AMLX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

0.00

-100%

-0.347

-36.82%

-0.297

-29.36%

-0.313

-31.88%

Estimates Revision

The market is revising No Change the revenue expectations for Amylyx Pharmaceuticals, Inc. (AMLX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -15.76%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-7.53%

In Past 3 Month

Stock Price

Go Down

-15.76%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast AMLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMLX is 20.22 USD with a low forecast of 16.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

16.00

Averages

20.22

High

25.00

Current: 0.000

Low

16.00

Averages

20.22

High

25.00

BofA

Buy

maintain

$16 -> $15

2025-12-19

Reason

BofA

Price Target

$16 -> $15

2025-12-19

maintain

Buy

Reason

BofA lowered the firm's price target on Amylyx to $15 from $16 and keeps a Buy rating on the shares after the company reported Q3 earnings and confirmed a cash runway to 2028 due to recent financing. The "driver of the story" remains pivotal Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia expected in Q3 of 2026, the analyst tells investors.

Mizuho

Graig Suvannavejh

Outperform

maintain

$16 -> $18

2025-11-10

Reason

Mizuho

Graig Suvannavejh

Price Target

$16 -> $18

2025-11-10

maintain

Outperform

Reason

Mizuho analyst Graig Suvannavejh raised the firm's price target on Amylyx to $18 from $16 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q3 report.

H.C. Wainwright

Andrew Fein

maintain

$16 -> $20

2025-11-07

Reason

H.C. Wainwright

Andrew Fein

Price Target

$16 -> $20

2025-11-07

maintain

Reason

H.C. Wainwright analyst Andrew Fein raised the firm's price target on Amylyx to $20 from $16 and keeps a Buy rating on the shares. With the pivotal LUCIDITY trial on track for topline data in 2026, the firm remains "enthusiastic about avexitide" and thinks it is positioned to become the first potential therapy for PBH, the analyst tells investors.

Mizuho

Outperform

upgrade

$12 -> $16

2025-10-29

Reason

Mizuho

Price Target

$12 -> $16

2025-10-29

upgrade

Outperform

Reason

Mizuho raised the firm's price target on Amylyx to $16 from $12 and keeps an Outperform rating on the shares.

Citi

Hold -> Buy

upgrade

$12 -> $20

2025-10-17

Reason

Citi

Price Target

$12 -> $20

2025-10-17

upgrade

Hold -> Buy

Reason

Citi raised the firm's price target on Amylyx to $20 from $12 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.

Baird

Joel Beatty

Outperform

upgrade

$10 -> $19

2025-10-16

Reason

Baird

Joel Beatty

Price Target

$10 -> $19

2025-10-16

upgrade

Outperform

Reason

Baird analyst Joel Beatty raised the firm's price target on Amylyx to $19 from $10 and keeps an Outperform rating on the shares. The firm updated its model given increased confidence in Avextide's penetration rate in PBH.

Valuation Metrics

The current forward P/E ratio for Amylyx Pharmaceuticals Inc (AMLX.O) is -8.87, compared to its 5-year average forward P/E of 0.79. For a more detailed relative valuation and DCF analysis to assess Amylyx Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

0.79

Current PE

-8.87

Overvalued PE

14.23

Undervalued PE

-12.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

1.51

Current EV/EBITDA

-8.15

Overvalued EV/EBITDA

13.60

Undervalued EV/EBITDA

-10.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1125.49

Current PS

12059.03

Overvalued PS

5026.85

Undervalued PS

-2775.87

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 120.44% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 120.44% over the last month.

Sold

Bought

AMLX News & Events

Events Timeline

No data

News

2.0

01-05NASDAQ.COM

Amylyx Pharmaceuticals (AMLX) Hits Oversold RSI of 29.0 Amid Heavy Selling

5.0

2025-12-26NASDAQ.COM

Amylyx and MAIA Executives Increase Stock Holdings Amid Market Fluctuations

9.0

2025-12-17NASDAQ.COM

Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise

People Also Watch

Frequently Asked Questions

What is Amylyx Pharmaceuticals Inc (AMLX) stock price today?

The current price of AMLX is 12.19 USD — it has increased 3.04 % in the last trading day.

What is Amylyx Pharmaceuticals Inc (AMLX)'s business?

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.

What is the price predicton of AMLX Stock?

What is Amylyx Pharmaceuticals Inc (AMLX)'s revenue for the last quarter?

Amylyx Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Amylyx Pharmaceuticals Inc (AMLX)'s earnings per share (EPS) for the last quarter?

Amylyx Pharmaceuticals Inc. EPS for the last quarter amounts to -0.37 USD, decreased -65.42 % YoY.

What changes have occurred in the market's expectations for Amylyx Pharmaceuticals Inc (AMLX)'s fundamentals?

How many employees does Amylyx Pharmaceuticals Inc (AMLX). have?

Amylyx Pharmaceuticals Inc (AMLX) has 123 emplpoyees as of January 09 2026.

What is Amylyx Pharmaceuticals Inc (AMLX) market cap?

Today AMLX has the market capitalization of 1.30B USD.